A 3-Month, Follow-Up, Randomized, Placebo-Controlled Study of Repetitive Transcranial Magnetic Stimulation in Depression

Effects of repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex on the attentional processing of emotional information in major depression: A pilot study

“…Koerselman et al, 2004), with high stimulus frequencies (10 HZ), high stimulus intensities (motor threshold above 110 %) and more and frequent pulses (1560 pulses per session), probably having greater antidepressant potency. Secondly, apart from the potential doseresponse effect, the higher response rate in the present study may also be attributed to the use of the MRI guided identification procedure of the left DLPFC.…”

Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): Sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder

“…TMS exerts significant antidepressant effects when applied to the left dorsolateral prefrontal cortex (DLPFC). This antidepressant effect has been replicated in numerous randomized, sham-controlled clinical trials, and has been summarized in several meta-analyses, supported by randomized controlled trials (Eranti et al, 2007;Fitzgerald et al, 2009a;George et al, 2010;Koerselman et al, 2004;Mogg et al, 2008; Contents lists available at SciVerse ScienceDirect journal homepage: www.elsevier.com/locate/psychres O'Reardon et al, 2007;Ray et al, 2010;Stern et al, 2007;Grunhaus et al, 2003) and meta-analyses (Holtzheimer et al, 2001;Kozel and George,2002;Martin et al, 2003;Gross et al, 2007;Lam et al, 2008;Slotema et al, 2010;Schutter,2009).…”

Neurobiological Mechanisms of the Placebo Effect

“…Major depression is another useful model to examine neurobiological mechanisms of the placebo effect, because placebo responses are common in antidepressant trials of many interventions, including medication, psychotherapy, and somatic treatments (DeRubeis et al, 1999(DeRubeis et al, , 2005Kirsch and Sapirstein, 1998;Enserink, 1999;Khan et al, 2000;Walsh et al, 2002;Koerselman et al, 2004). As in clinical trials for other medical conditions, the effectiveness of a new antidepressant is determined by comparing an active treatment with a controlled comparison condition.…”